Wolverine Blend (BPC-157 / TB-500) (5 mg Vial) Dosage Protocol
Wolverine Blend combines BPC-157 and TB-500 in a single vial — the two most-studied tissue-repair peptides, working through complementary mechanisms. This page covers the 5 mg vial.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and combined dosing protocol
TB-500 Protocol (2 mL Reconstitution = 2.5 mg/mL)
| Week | Dose (mcg) | Units (per injection) (mL) | Frequency |
|---|---|---|---|
| Weeks 1–4 | 1,250 mcg (1.25 mg) | 50 units (0.50 mL) | Twice weekly |
| Weeks 5–12 | 1,250 mcg (1.25 mg) | 50 units (0.50 mL) | Once weekly |
Route: Subcutaneous injection. The loading phase (Weeks 1–4) uses twice-weekly dosing to establish tissue saturation, followed by a maintenance phase (Weeks 5–12) at once weekly.
TB-500 Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
BPC-157 Protocol (2 mL Reconstitution = 2.5 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) | Frequency |
|---|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 10 units (0.10 mL) | Once daily |
| Weeks 3–8 | 500 mcg (0.50 mg) | 20 units (0.20 mL) | Once daily |
| Weeks 9–12 | 250 mcg (0.25 mg) | 10 units (0.10 mL) | Once daily |
Route: Subcutaneous injection, preferably near the site of injury. Preclinical research commonly uses 250–500 mcg per day for musculoskeletal applications. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
BPC-157 Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week combined protocol with the schedules above.
| Item | Quantity |
|---|---|
| TB-500 Vials (5 mg each) | 8 weeks ≈ 3 vials 12 weeks ≈ 4 vials 16 weeks ≈ 5 vials |
| BPC-157 Vials (5 mg each) | 8 weeks ≈ 5 vials 12 weeks ≈ 7 vials 16 weeks ≈ 8 vials |
| Insulin Syringes (U-100) | 8 weeks: 68 syringes (TB-500: 12 + BPC-157: 56) 12 weeks: 100 syringes (TB-500: 16 + BPC-157: 84) 16 weeks: 132 syringes (TB-500: 20 + BPC-157: 112) |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (8 total vials): 16 mL → 2 × 10 mL bottles 12 weeks (11 total vials): 22 mL → 3 × 10 mL bottles 16 weeks (13 total vials): 26 mL → 3 × 10 mL bottles |
| Alcohol Swabs | 8 weeks: ~160 swabs → recommend 2 × 100-count boxes 12 weeks: ~232 swabs → recommend 3 × 100-count boxes 16 weeks: ~304 swabs → recommend 4 × 100-count boxes |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
BPC-157 provides local cytoprotection, angiogenesis, and tendon-cell migration. TB-500 provides systemic actin regulation and cell migration. The two work through complementary mechanisms; they are commonly combined in connective-tissue research protocols.
Potential Benefits & Side Effects
Potential Benefits
- Synergistic tissue-repair effects.
- Established research-grade combination.
- Suitable for both local and systemic protocols.
Side Effect Profile
- Combined profile of components.
- Injection-site reactions.
- Generally well-tolerated.
Lifestyle Factors
- Pair with appropriate physical therapy.
- Adequate protein and collagen-supportive nutrients.
- Avoid NSAIDs during early-phase repair.
Injection Technique
- Subcutaneous, abdomen/thigh/upper arm. Rotate sites if dosing twice daily.